^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Ocrevus (ocrelizumab)
i
Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biogen, Roche
Drug class:
CD20 inhibitor
Related drugs:
2d
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche
Trial initiation date
|
Ocrevus (ocrelizumab)
6d
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis (clinicaltrials.gov)
P4, N=50, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
Enrollment open
|
Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
7d
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients (clinicaltrials.gov)
P=N/A, N=2604, Completed, Novartis Pharmaceuticals
New trial • HEOR • Real-world evidence
|
Ocrevus (ocrelizumab)
13d
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
P3, N=360, Recruiting, Novartis Pharmaceuticals | N=215 --> 360
Enrollment change • Head-to-Head
|
Ocrevus (ocrelizumab)
16d
20230309: A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis (2024-512914-16-00)
P2/3, N=375, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
19d
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche | N=235 --> 360
Enrollment change • Trial initiation date
|
Ocrevus (ocrelizumab)
1m
OPA: Ocrelizumab for Psychosis by Autoimmunity (clinicaltrials.gov)
P1/2, N=40, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Jun 2025 --> Jun 2028
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
1m
Operetta III: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov)
P2, N=25, Not yet recruiting, Hoffmann-La Roche
New P2 trial
|
Ocrevus (ocrelizumab)
1m
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche
Trial initiation date
|
Ocrevus (ocrelizumab)
2ms
Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database. (PubMed, Mult Scler Relat Disord)
Anti-CD20 antibodies require careful ocular monitoring, particularly in multiple sclerosis patients. The elevated blepharospasm risks with ofatumumab and dyschromatopsia with rituximab highlights potential CNS-and optic pathway-related effects that warrant further study to improve MS treatment safety.
Journal • Adverse events
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
2ms
OCREFINA: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis (clinicaltrials.gov)
P4, N=5, Enrolling by invitation, University of California, San Francisco | Recruiting --> Enrolling by invitation | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
Enrollment status • Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
2ms
21-PP-23: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY (2024-516433-13-00)
P2/3, N=89, Recruiting, Centre Hospitalier Universitaire De Nice | Not yet recruiting --> Recruiting
Enrollment open
|
Ocrevus (ocrelizumab)
Share via
